A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low- frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia

Cancer Research

Volumn 59, Issue 11, 1999, Pages 2675-2681

  Molldrem, Jeffrey J ^a   Lee, Peter P ^b   Wang, Changqing ^a   Champlin, Richard E ^a   Davis, Mark M ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA A2 ANTIGEN; TETRAMER;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CHRONIC MYELOID LEUKEMIA; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MEMORY CELL; PRIORITY JOURNAL;

FLOW CYTOMETRY; HLA-A2 ANTIGEN; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MYELOBLASTIN; PEPTIDE FRAGMENTS; PHENOTYPE; SERINE ENDOPEPTIDASES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033152972     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Clave, E., Molldrem, J., Hensel, N., Raptis, A., and Barrett, A. J. Donor-recipient polymorphism of the proteinase 3 gene: a potential target for T cell alloresponses to myeloid leukemia. J. Immunother., 22: 1-6, 1999.
2. Molldrem, J., Dermime, S., Parker, K., Jiang, Y. Z., Mavroudis, D., Hensel, N., Fukushima, P., and Barrett, A. J. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood, 88: 2450-2457, 1996.
3. Molldrem, J. J., Clave, E., Jiang, Y. Z., Mavroudis, D., Raptis, A., Hensel, N., Agarwala, V., and Barrett, A. J. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood, 90: 2529-2534, 1997.
4. Papadopoulos, K., Suciu-Foca, N., Hesdorffer, C., Tugulea, S., Maffei, A., and Harris, P. Naturally processed tissue-and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood, 90: 4938-4946, 1997.
5. Dengler, R., Munstermann, U., al-Batran, S., Hausner, I., Faderl, S., Nerl, C., and Emmerich, B. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol., 89: 250-257, 1995.
6. Altman, J. D., Moss, P. A. H., Goulder, P. J. R., Barouch, D. H., McHeyzer-Williams, M. G., Bell, J. I., McMichael, A. J., and Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science (Washington DC), 274: 94-96, 1996.
7. Gallimore, A., Glithero, A., Godkin, A., Tissot, A. C., Pluckthun, A., Elliott, T., Hengartner, H., and Zinkernagel, R. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualized using soluble telrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med., 187: 1383-1393, 1998.
8. Callan, M. F., Tan, L., Annels, N., Ogg, G. S., Wilson, J. D., O'Callaghan, C. A., Steven, N., McMichael, A. J., and Rickinson, A. B. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J. Exp. Med., 187: 1395-1402, 1998.
9. Wilson, J. D., Ogg, G. S., Allen, R. L., Goulder, P. J., Kelleher, A., Sewell, A. K., O'Callaghan, C. A., Rowland-Jones, S. L., Callan, M. F., and McMichael, A. J. Oligoclonal expansions of CD8(+) T cells in chronic HIV infection are antigen specific. J. Exp. Med., 188: 785-790, 1998.
10. McMichael, A. J., and O'Callaghan, C. A. A new look at T cells. J. Exp. Med., 187: 1367-1371, 1998.
11. McLaughlin-Taylor, E., Pande, H., Forman, S. J., Tanamachi, B., Li, C. R., Zaia, J. A., Greenberg, P. D., and Riddell, S. R. Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J. Med. Virol., 43: 103-110, 1994.
12. Riddell, S. R., and Greenberg, P. D. Principles for adoptive T cell therapy of human viral diseases. Annu. Rev. Immunol. 13: 545-586, 1995.
13. Salter, R. D., and Cresswell, P. Impaired assembly and transport of HLA-A and -B antigens in a mutant TXB cell hybrid. EMBO J., 5: 943-949, 1986.
14. Anderson, K., Cresswell, P., Gammon, M., Hermes, J., Williamson, A., and Zweerink, H. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J. Exp. Med., 174: 489-492, 1991.
15. Brouwer, E., Stegeman, C. A., Huitema, M. G., Limburg, P. C., Kallenberg, C. G. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin. Exp. Immunol., 98: 448-453, 1994.
16. Mackinnon, S., Papadopoulos, E. B., Carabasi, M. H., Reich, L., Collins, N. H., Boulad, F., Castro-Malaspina, H., Childs, B. H., Gillio, A. P., and Kernan, N. A. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood, 86: 1261-1268, 1995.
17. Giralt, S. A., and Kolb, H. J. Donor lymphocyte infusions. Curr. Opin. Oncol., 8: 96-102, 1996.
18. Kolb, H. J., and Holler, E. Adoptive immunotherapy with donor lymphocyte transfusions. Curr. Opin. Oncol., 9: 139-145, 1997.
19. Herr, W., Schneider, J., Lohse, A. W., Meyer zum Buschenfelde, K. H., and Wolfel T. Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens. J. Immunol. Methods, 191: 131-142, 1996.
20. Disis, M. L., Smith, J. W., Murphy, A. E., Chen, W., and Cheever M. A. In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/ neu protooncogene protein. Cancer Res., 54: 1071-1076, 1994.
21. Alexander-Miller, M. A., Leggatt, G. R., and Berzofsky, J. A. Selective expansion of high-or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. USA, 93: 4102-4107, 1996.
22. Morgan, D. J., Kreuwel, H. T. C., Fleck, S., Levitsky, H. I., Pardoll, D. M., and Sherman, L. A. Activation of low avidity CTL specific for a self epitope results in tumor rejection but not autoimmunity. J. Immunol., 160: 643-651, 1998.
23. Boussiotis, V. A., Freeman, G. J., Gribben, J. G., and Nadler, L. M. The role of B7-1/B7-2: CD28/CLTA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol. Rev., 153: 5-26, 1996.
24. Staveley, O. C. K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., and Levitsky, H. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA, 95: 1178-1183, 1998.